TP53 and hematopoietic and lymphoid cell neoplasm: TP53 mutation status was not correlated with LP-284 sensitivity in these hematologic cancer cell lines [28–32] (Figure 1C) or in the NCI-60 panel [33] where LP-284’s antitumor activities were screened earlier (Zhou et al., 2022 Society of Hematologic Oncology conference abstract # MCL319) (p > 0.05; Figure 1D).